Phase 4 Sleep Disorders Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to give their informed consent to take part in the study
- People who have regular outpatient follow-up appointments at the Massachusetts General Hospital (MGH) transplant center
- People who had their most recent kidney transplant at least 1 year ago
- People who are currently taking the immediate-release form of a medication called tacrolimus as their ongoing anti-rejection treatment
- People whose tacrolimus medication level in the blood has been stable and within the target range (5–10 ng/ml) for at least the past 3 months
- People whose kidney function has been stable, with less than 20% change between their two most recent kidney function test results
- People whose primary language is English or Spanish
Who may not be able to join:
- People who received two organs in their transplant (for example, a kidney and another organ at the same time)
- People who have experienced a transplant rejection episode in the last three months
- People with a history of moderate to severe dementia
- People with a history of Parkinson's disease
- People with severe liver disease that is not well controlled
- People with an active cancer diagnosis
- People with depression or anxiety that is not currently well controlled
- People who are blind
- People who are deaf
- People with intellectual disabilities
- People who are pregnant
- People whose kidney function is very low at the time of joining the study (confirm with trial site)
- People whose bilirubin level (a marker of liver function) is above a certain threshold at the time of joining (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Leonardo V. Riella, MD, PhD, Massachusetts General Hospital
Phone: 6177240345
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The difference in changes of neurocognitive function in intermediate-term (Total cognition composite, standard score); The difference in changes of neurocognitive function in intermediate-term (Fluid composite, standard score); The difference in changes of neurocognitive function in intermediate-term (Crystallized composite, standard score); The difference in changes of neurocognitive function in intermediate-term (Total cognition composite, T score); The difference in changes of neurocognitive function in intermediate-term (Fluid composite, T score); The difference in changes of neurocognitiv...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.